Chronic Gout Market

Market Overview:

The 7 major chronic gout markets are expected to exhibit a CAGR of 11.12% during 2024-2034.

The chronic gout market has been comprehensively analyzed in IMARC's new report titled "Chronic Gout Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Chronic gout is a form of inflammatory arthritis characterized by recurrent attacks of severe joint pain, swelling, and redness. It is caused by the buildup of urate crystals within the joints due to elevated levels of uric acid in the blood. The most usually affected joint is the big toe, although various other joints like the knees, elbows, and wrists can also be involved. Symptoms typically include sudden, intense pain that often occurs at night, accompanied by swelling, redness, and warmth over the affected joint. These indications can persist and lead to joint damage and deformities if the condition is not effectively managed. Diagnosing chronic gout involves a combination of clinical evaluation and laboratory tests. Doctors may inquire about a patient's medical history, symptoms, and lifestyle factors, such as diet and alcohol consumption. Additionally, they may perform joint fluid analysis to check for the presence of urate crystals, which are characteristic of gout.

The escalating prevalence of the buildup of uric acid in the body, which leads to inflammation and intense pain, is primarily driving the chronic gout market. In addition to this, the inflating utilization of potent medications, such as non-steroidal anti-inflammatory drugs (NSAIDs), colchicine, and xanthine oxidase inhibitors is also creating a positive outlook for the market. These drugs aid in alleviating pain and reducing inflammation during gout attacks while also preventing the formation of urate crystals. Moreover, the widespread adoption of lifestyle modifications, including dietary adjustments and weight management, to help in decreasing the concentrations of uric acid in the blood and mitigating the frequency and severity of the condition is further bolstering the market growth. Apart from this, the increasing research into gene therapy, focused on manipulating or replacing genes that may be implicated in the dysfunction of purine metabolism, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of urate-lowering therapies like allopurinol and febuxostat, aimed at reducing uric acid levels in the blood, is also augmenting the market growth. Furthermore, the rising demand for biologic therapies, which target specific immune responses to control inflammation and improve the quality of life for patients, is expected to drive the chronic gout market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the chronic gout market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for chronic gout and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the chronic gout market in any manner.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the chronic gout market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the chronic gout market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape

This report also provides a detailed analysis of the current chronic gout marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report

Market Insights

• How has the chronic gout market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the chronic gout market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the chronic gout market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of chronic gout across the seven major markets?
• What is the number of prevalent cases (2018-2034) of chronic gout by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of chronic gout by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with chronic gout across the seven major markets?
• What is the size of the chronic gout patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of chronic gout?
• What will be the growth rate of patients across the seven major markets?
   

Chronic Gout: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for chronic gout drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the chronic gout market?
• What are the key regulatory events related to the chronic gout market?
• What is the structure of clinical trial landscape by status related to the chronic gout market?
• What is the structure of clinical trial landscape by phase related to the chronic gout market?
• What is the structure of clinical trial landscape by route of administration related to the chronic gout market?